Common use of Representative Warrants Clause in Contracts

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Shares, representing six percent (6%) of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 125% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Sharesshares of common stock, representing six seven percent (67%) of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date one hundred eightieth (180th) days after the commencement of issuance sales of the Offering and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 125110% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on after the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on following the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Sharesshares of common stock, representing six five percent (65.0%) of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth three year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 125120% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions. The Representatives’ Warrants shall also have customary anti-dilution provisions for stock dividends, splits, mergers, and any future stock issuance, etc., at a price(s) below said exercise price per share and shall provide for automatic exercise immediately prior to expiration. The Representatives’ Warrants will contain such other terms and conditions no less favorable to Representatives than the term and conditions generally available to an unaffiliated third party under the same or similar circumstances.

Representative Warrants. The On the Closing Date and each Option Closing Date, if any, the Company hereby agrees to shall issue to the Representative Representatives (and/or its their designees) on the Closing Date warrants (“Representative Warrants”) to purchase such a number of Ordinary Shares, representing six shares of Common Stock equal to eight percent (68%) of the total aggregate number of Offered SecuritiesShares sold in the Offering, including any Option Shares sold in the Over-Allotment Option, if any (the "Representative Warrants"). The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”)F, shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is Common Stock equal to 125110% of the public offering price of each Unit and expire five (5) years from the Firm SharesEffective Date. The Representative’s Warrant Agreement Representatives understand and the Ordinary Shares issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees agree that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Representative Warrants and the shares of Common Stock issuable upon exercise of the Representative Warrants (the "Representative Warrant Shares Shares") during the one hundred eighty (180) days beginning on after the date of commencement of sales of the Offering Effective Date and by its acceptance thereof the Representatives shall agree that it they will not sell, transfer, assign, pledge or hypothecate the Representative’s Representative Warrants, or any portion thereof, or the Representative Warrant Shares, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on following the date of commencement of sales of the Offering Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the OfferingOffering (or any successor of the any of the Representatives or of any such Underwriter or selected dealer), or (ii) a bona fide officer officer, manager, partner or partner member of any of the Representative Representatives or of any such Underwriter or selected dealerdealer (or any officer, manager, partner or member of any such successor); and only if any such transferee agrees to the foregoing lock-up restrictions. Delivery of the applicable Representative Warrants shall be made on the Closing Date and each Option Closing Date, if any, and shall be issued in the name or names and in such authorized denominations as the Representatives may request.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Sharesshares of common stock, representing six percent (6%) 5% of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date one hundred eightieth (180th) days after the commencement of issuance sales of the Offering and expiring on the fifth five-year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 125% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on after the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on following the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Sharesshares of common stock, representing six seven percent (67%) of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 125110% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Sharesshares of common stock, representing six seven percent (67%) of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●]4.4, which is equal to 125110% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The On the Closing Date and each Option Closing Date, if any, the Company hereby agrees to shall issue to the Representative Representatives (and/or its their designees) on warrants to purchase a number of shares of Common Stock equal to eight percent (8%) of the Closing Date warrants aggregate number of Shares sold in the Offering, including any Option Shares sold in the Over-Allotment Option, if any (the “Representative Warrants”) to purchase such number of Ordinary Shares, representing six percent (6%) of the total number of Offered Securities). The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”)F, shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is Common Stock equal to 125110% of the public offering price of each Unit and expire five (5) years from the Firm SharesEffective Date. The Representative’s Warrant Agreement Representatives understand and the Ordinary Shares issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees agree that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Representative Warrants and the shares of Common Stock issuable upon exercise of the Representative Warrants (the “Representative Warrant Shares Shares”) during the one hundred eighty (180) days beginning on after the date of commencement of sales of the Offering Effective Date and by its acceptance thereof the Representatives shall agree that it they will not sell, transfer, assign, pledge or hypothecate the Representative’s Representative Warrants, or any portion thereof, or the Representative Warrant Shares, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on following the date of commencement of sales of the Offering Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the OfferingOffering (or any successor of the any of the Representatives or of any such Underwriter or selected dealer), or (ii) a bona fide officer officer, manager, partner or partner member of any of the Representative Representatives or of any such Underwriter or selected dealerdealer (or any officer, manager, partner or member of any such successor); and only if any such transferee agrees to the foregoing lock-up restrictions. Delivery of the applicable Representative Warrants shall be made on the Closing Date and each Option Closing Date, if any, and shall be issued in the name or names and in such authorized denominations as the Representatives may request.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Shares, representing six percent (6%) 7.5% of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is equal to 125135% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants (“Representative Warrants”) to purchase such number of Ordinary Sharesshares of common stock, representing six percent (6%) 5% of the total number of Offered Securities. The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”), shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date one hundred eightieth (180th) days after the commencement of issuance sales of the Offering and expiring on the fifth five-year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●]9.375, which is equal to 125% of the offering price of the Firm Shares. The Representative’s Warrant Agreement and the Ordinary Shares shares of Common Stock issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days beginning on after the date of commencement of sales of the Offering and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on following the date of commencement of sales of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

Representative Warrants. The On the Closing Date and each Option Closing Date, if any, the Company hereby agrees to shall issue to the Representative (and/or its designees) on warrants to purchase a number of shares of Common Stock equal to nine percent (9%) of the Closing Date warrants aggregate number of Shares sold in the Offering, including any Option Shares sold in the Over-Allotment Option, if any (the “Representative Warrants”) to purchase such number of Ordinary Shares, representing six percent (6%) of the total number of Offered Securities). The agreement(s) representing the Representative Warrants, in the form attached hereto as Exhibit B (the “Representative’s Warrant Agreement”)F, shall be exercisable at any time, and from time to time, in whole or in part, commencing from the date of issuance and expiring on the fifth year anniversary of the commencement of sales of the Offering at an initial exercise price per share of $[●], which is Common Stock equal to 125110% of the public offering price of each Unit and expire five (5) years from the Firm SharesEffective Date. The Representative’s Warrant Agreement and the Ordinary Shares issuable upon exercise thereof (the “Warrant Shares”) are hereinafter referred to together as the “Representative’s Securities.” The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Representative Warrants and the Warrant Shares issuable upon exercise of the Representative Warrants during the one hundred eighty (180) days beginning on after the date of commencement of sales of the Offering Effective Date and by its acceptance thereof the Representative shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Representative Warrants, or any portion thereof, or the Warrant Shares, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days beginning on following the date of commencement of sales of the Offering Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, Offering (or (ii) a bona fide officer or partner any successor of the Representative or of any such Underwriter or selected dealer), or (ii) a bona fide officer, manager, partner or member of the Representative or of any such Underwriter or selected dealer (or any officer, manager, partner or member of any such successor); and only if any such transferee agrees to the foregoing lock-up restrictions. Delivery of the applicable Representative Warrants shall be made on the Closing Date and each Option Closing Date, if any, and shall be issued in the name or names and in such authorized denominations as the Representative may request.